Amyotrophic lateral sclerosis IgG-treated neuromuscular junctions develop sensitivity to L-type calcium channel blocker

Muscle and Nerve

Volumn 23, Issue 4, 2000, Pages 543-550

  Fratantoni, Silvina A ^a   Weisz, Gisela ^b   Pardal, Ana M ^c   Reisin, Ricardo C ^c   Uchitel, Osvaldo D ^b,d  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b INSTITUTO DE FISIOLOGÍA   (Argentina)

^c HOSPITAL BRITÁNICO DE BUENOS AIRES   (Argentina)

^d Fac Cie E   (Argentina)

Author keywords

Amyotrophic lateral sclerosis; Calcium channels; Neuromuscular junction; Nitrendipine; Transmitter release

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; IMMUNOGLOBULIN G; NITRENDIPINE;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM TRANSPORT; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOTHERAPY; MALE; MOUSE; NERVE CELL NECROSIS; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VOLTAGE CLAMP;

ADULT; AGED; ANIMALS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; EVOKED POTENTIALS; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MICE; MIDDLE AGED; MOTOR NEURON DISEASE; MUSCLE, SKELETAL; NEUROMUSCULAR JUNCTION; NITRENDIPINE; OMEGA-AGATOXIN IVA; OMEGA-CONOTOXIN GVIA; REFERENCE VALUES;

EID: 0034082626     PISSN: 0148639X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4598(200004)23:4<543::AID-MUS13>3.0.CO;2-S     Document Type: Article

References (37)

1. Agustine GJ, Charlton MP, Smith SJ. Calcium action in synaptic transmitter release. Annu Rev Neurosci 1987;10: 633-693.
2. Appel SH, Engelhardt JI, Garcia J, Stefani E. Immunoglobulins from animal models of motor neuron disease and from human amyotrophic lateral sclerosis patients passively transfer physiological abnormalities to the neuromuscular junction. Proc Natl Acad Sci USA 1991;88:647-651.
3. Atchinson WD. Dihydropyridine-sensitive and -insensitive components of acetylcholine release from rat motor nerve terminals. J Pharmacol Exp Ther 1989;251:672-678.
4. Brady S. Motor-neuron diseases. Interfering with the runners. Nature 1995;375:12-13.
5. Brown RH Jr. Superoxide dismutase and familial amyotrophic lateral sclerosis: new insights into mechanisms and treatments. Ann Neurol 1996;39:145-146.
6. Deisseroth K, Heist EK, Tsien RW. Translocation of calmodulin to the nucleus supports CREB phosphorylation in hippocampal neurons. Nature 1998;392:198-202.
7. Drachman DB, Fishman PS, Rothstein JD, Motomura M, Lang B, Vincent A, Mellits ED. Amyotrophic lateral sclerosis: an autoimmune disease? Adv Neurol 1995;68:59-66.
8. Fukunaga H, Engel AG, Lang B, Newsom-Davis J, Vincent A. Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones. Proc Natl Acad Sci USA 1983;80:7636-7640.
9. Hubbard JI, Llinás R, Quastel DMJ. Electrophysiological analysis of synaptic transmission. London: Arnold; 1969.
10. Katz E, Ferro P, Weisz G, Uchitel OD. Calcium channels involved in synaptic transmission at the mature and regenerating mouse neuromuscular junction. J Physiol (Lond) 1996; 497:687-697.
11. 2+ channel blocker neurotoxins on transmitter release and presynaptic currents at the mouse neuromuscular junction. Br J Pharmacol 1997;121:1531-1540.
12. 1 subunit. Ann Neurol 1994;35:164-171.
13. Lee MK, Marszalek JR, Cleveland DW. A mutant neurofilament subunit causes massive, selective motor neuron death: implications for the pathogenesis of human motor neuron disease. Neuron 1994;13:975-988.
14. Lennon VA, Kryzer TJ, Griesmann GE, O'Suilleabhain PE, Windebank AJ, Woppmann A, Miljanich GP, Lambert EH. Calcium channel antibodies in the Lambert Eaton myasthenic syndrome and other paraneoplastic syndromes. N Engl J Med 1995;332:1467-1474.
15. Martin AR. Quantal nature of synaptic transmission. Physiol Rev 1966;46:51-66.
16. Maselli RA, Wollman RL, Leung C, Distad B, Palombi S, Richman DP, Salazar-Grueso EF, Roos RP. Neuromuscular transmission in amyotrophic lateral sclerosis. Musde Nerve 1993; 16:1193-1203.
17. McLachlan EM, Martin AR. Non-linear summation of endplate potentials in the frog and mouse. J Physiol (Lond) 1981; 311:307-324.
18. Nyormoi O. Proteolytic activity in amyotrophic lateral sclerosis IgG preparations. Ann Neurol 1996;40:701-706.
19. O'Shaughnessy TJ, Van H, Kim J, Middlekauff EH, Lee KW, Phillips LH, Kim J, Kim YI. Amyotrophic lateral sclerosis: serum factors enhance spontaneous and evoked transmitter release at the neuromuscular junction. Muscle Nerve 1998;21: 81-90.
20. Penner R, Dreyer F. Two different presynaptic calcium currents in mouse motor nerve terminals. Pflügers Arch 1986; 406:190-197.
21. Protti DA, Reisin R, Mackinley TA, Uchitel OD. Calcium channel blockers and transmitter release at the normal human neuromuscular junction. Neurology 1996;46:1391-1396.
22. 2+ currents blocked by the spider toxin ω-Aga-IVA. Neuroreport 1993;5:333-336.
23. Rothstein JD, Dykes-Hoberg M, Pardo CA, Bristol LA, Jin L, Kunel RW, Kanai Y, Hediger MA, Wang Y, Schielke JP, Welty DF. Antisense knockout of glutamate transporters reveals a predominant role for astroglial glutamate transport in excitotoxicity and clearance of extracellular glutamate. Neuron 1996;16:675-686.
24. Santa Fé M, Uchitel OD. L- and P-type calcium channels mediate transmitter release in botulinum toxin treated neuromuscular junctions. Soc Neurosci Abstr 1997;23:470-472.
25. Schwartz MS, Swash M. Neurophysiological changes in motor neuron disease. In: Leigh PN, Swash M, eds. Motor neuron disease: biology and management. New York: Springer; 1995. p 331-344.
26. Shaw PJ. Excitotoxicity and motor neuron disease: a review of the evidence. J Neurol Sci 1994;124:6-13.
27. Siddique T, Deng HX. Genetics of amyotrophic lateral sclerosis. Hum Mol Genet 1996;5:1465-1470.
28. Siddique T, Figlewicz DA, Pericak-Vance MA, Haines JL, Rouleau G, Jeffers AJ, Sapp P, Hung WY, Bebout J, McKenna-Yasek D, et al. Linkage of a gene causing familial amyotrophic lateral sclerosis to chromosome 21 and evidence of genetic locus heterogeneity. N Engl J Med 1991;324:1381-1384.
29. Smith DO, Conklin MW, Jensen PJ, Atchison WD. Decreased calcium currents in motor nerve terminals of mice with Lambert-Eaton myasthenic syndrome. J Physiol (Lond) 1995; 15;487:115-123.
30. Smith RG, Siklos L, Alexianu ME, Engelhardt JI, Mosier DR, Colom L, Habib Mohamed A, Appel SH. Autoimmunity and ALS. Neurology 1996;47(suppl):S40-S46.
31. Uchitel OD, Appel SH, Crawford F, Szczupak L. Immunoglobulins from amyotrophic lateral sclerosis patients enhance spontaneous transmitter release from motor nerve terminals. Proc Natl Acad Sci USA 1988;85:7371-7374.
32. Uchitel OD, Protti DA, Sánchez V, Cherksey BD, Sugimori M, Llinás R. P-type voltage-dependent calcium channel mediate presynaptic calcium influx and transmitter release in mammalian synapses. Proc Natl Acad Sci USA 1992;89:3330-3333.
33. Uchitel OD, Scornik F, Protti DA, Fumberg CG, Alvarez V, Appel SH. Long-term neuromuscular dysfunction produced by passive transfer of amyotrophic lateral sclerosis immunoglobulins. Neurology 1992;42:2175-2180.
34. Vincent A, Drachman DB. Amyotrophic lateral sclerosis and antibodies to voltage-gated calcium channels - new doubts. Ann Neurol 1996;40:691-693.
35. Williams DB, Windebank AJ. Motor neuron disease (amyotrophic lateral sclerosis). Mayo Clinic Proc 1991;66:54-82.
36. World Federation of Neurology Research Group on Neuromuscular Diseases. El Escorial World Federation of Neurología criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1994;124(suppl):96-107.
37. Zar JH. Biostatistical analysis, 3rd ed. Englewood Cliffs, NJ: Prentice-Hall 1996.